Delcath Systems Dirección

Dirección controles de criterios 1/4

El CEO de Delcath Systems' es Gerard Michel , nombrado en Oct 2020, tiene una permanencia de 3.5 años. compensación anual total es $2.52M, compuesta por 21.3% salario y 78.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.19% de las acciones de la empresa, por valor de $1.59M. La antigüedad media del equipo directivo y de la junta directiva es de 1.5 años y 4 años, respectivamente.

Información clave

Gerard Michel

Chief Executive Officer (CEO)

US$2.5m

Compensación total

Porcentaje del salario del CEO	21.3%
Permanencia del CEO	3.6yrs
Participación del CEO	1.2%
Permanencia media de la dirección	1.6yrs
Promedio de permanencia en la Junta Directiva	4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gerard Michel en comparación con los beneficios de Delcath Systems?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$3m	US$538k	-US$48m
Sep 30 2023	n/a	n/a	-US$45m
Jun 30 2023	n/a	n/a	-US$34m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$521k	-US$37m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$2m	US$475k	-US$26m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$6m	US$113k	-US$24m

Compensación vs. Mercado: La compensación total de Gerard($USD2.52M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Gerard ha aumentado mientras la empresa no es rentable.

CEO

Gerard Michel (60 yo)

3.6yrs

Permanencia

US$2,520,314

Compensación

Mr. Gerard J. Michel, MS, MBA, serves as Chief Executive Officer and Director at Delcath Systems Inc since October 1, 2020. He had been Chief Financial Officer and Vice President of Corporate Development a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gerard Michel	CEO & Director	3.6yrs	US$2.52m	1.19% $ 1.7m
Sandra Pennell	Senior VP of Finance and Principal Financial & Accounting Officer	less than a year	sin datos	0.24% $ 346.7k
Martha Rook	Chief Operating Officer	less than a year	sin datos	sin datos
David Hoffman	General Counsel	2.3yrs	sin datos	0.29% $ 422.2k
Johnny John	Senior Vice President of Clinical Operations & Medical Affairs	3.3yrs	US$737.50k	0.0083% $ 11.9k
Vojislav Vukovic	Chief Medical Officer	less than a year	sin datos	0.50% $ 720.6k

1.6yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DCTH no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gerard Michel	CEO & Director	3.6yrs	US$2.52m	1.19% $ 1.7m
Roger Stoll	Independent Director	15.4yrs	US$188.48k	0.037% $ 52.9k
Elizabeth Czerepak	Independent Director	4.3yrs	US$188.51k	0% $ 0
Steven Salamon	Independent Director	4yrs	US$183.96k	0.32% $ 466.8k
John Sylvester	Independent Chairman	4.8yrs	US$204.88k	0.041% $ 59.9k
Gilad Aharon	Independent Director	4yrs	US$172.96k	0.12% $ 175.4k

4.1yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de DCTH se considera experimentada (4 años de antigüedad promedio).

Delcath Systems Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Executive Changes

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Insufficient new directors

Recent updates

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Forecast breakeven date pushed back to 2026

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?

No longer forecast to breakeven

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Insufficient new directors

Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates fall by 18%

Independent Chairman recently bought US$51k worth of stock

CEO & Director exercised options to buy US$171k worth of stock.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

New major risk - Shareholder dilution

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Consensus revenue estimates decrease by 46%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought US$55k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$18.20

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems Q2 2022 Earnings Preview

CEO & Director recently bought US$250k worth of stock

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding

Delcath Systems to raise $5M in stock and warrants offering

Delcath Systems: Revisiting A $5 Lottery Ticket

Price target decreased to US$21.20

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Price target decreased to US$22.00

Delcath Systems, Inc., Annual General Meeting, May 04, 2022

Consensus forecasts updated

Is Delcath Systems (NASDAQ:DCTH) Weighed On By Its Debt Load?

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT

Delcath Systems, Inc. Appoints Anthony Dias as its New Vice President of Finance

Delcath Systems, Inc. Announces Result of Single Center Study on Delcath’s CHEMOSAT Hepatic Delivery System Published in Melanoma Research

CEO & Director recently bought US$200k worth of stock

Price target increased to US$23.50

Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.96 loss per share (vs US$1.91 loss in 2Q 2020)

Delcath Systems, Inc. announced that it expects to receive $20 million in funding from Avenue Capital Group

Diving Into Delcath Systems

CEO & Director recently bought US$149k worth of stock